GSK ANNOUNCES SETTLEMENT BETWEEN VIIV HEALTHCARE, GILEAD SCIENCES
* GSK - SETTLEMENT RESOLVES LITIGATION RELATING TO BIKTARVY AND VIIV'S DOLUTEGRAVIR PATENTS AND ENTRY INTO A PATENT LICENCE AGREEMENT
* GSK - GILEAD WILL MAKE AN UPFRONT PAYMENT OF $1.25 BLN TO VIIV HEALTHCARE IN Q1 OF 2022
* GSK - GILEAD WILL ALSO PAY A 3% ROYALTY ON FUTURE US SALES OF BIKTARVY
* GSK - GILEAD'S OBLIGATION TO PAY ROYALTIES DOES NOT EXTEND INTO ANY PERIOD OF REGULATORY PAEDIATRIC EXCLUSIVITY
* GSK - GILEAD WILL ALSO PAY A 3% ROYALTY ON FUTURE US SALES OF BIKTARVY
* GSK - GILEAD WILL ALSO PAY A 3% ROYALTY ON FUTURE US SALES OF BIKTARVY
* GSK-FUTURE ROYALTY INCOME WILL BE RECORDED IN CO'S TOTAL AND ADJUSTED RESULTS IN THE INCOME STATEMENTS FOR 2022 TO 2027 INCLUSIVE
* GSK - VIIV HEALTHCARE, GSK AND SHIONOGI HAVE ALSO AGREED NOT TO ENFORCE THEIR PATENTS AGAINST ANY FUTURE PRODUCT CONTAINING BICTEGRAVIR
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.